Distribution and secretory pathways of prostate specific antigen, α1‐antichymotrypsin and prostate secretory granules in prostate cancers

Using 19 radical prostatectomy specimens, we studied the histological distribution of free prostate specific antigen (PSA), total PSA, α1‐antichymotrypsin (ACT) and prostate secretory granules (PSG) in both normal and cancerous cells of the prostate. After glutaraldehyde fixation, numerous fine eosinophilic droplets of PSG could be found mainly in the apical portions of normal acinous epithelial cells, but was markedly decreased in cancer cells. With antibodies against free PSA, normal acinous cells were granularly positive in the apical portion of the epithelium, which corresponded to the PSG, whereas cancer cells were diffusely positive. With antibodies against ACT, normal duct cells and cancer cells were often positive, but few normal acinous cells were positive. Presumably, these findings indicate that free PSA is secreted into the lumen as PSG in normal glands, but not by the same pathway in cancers where free PSA appears to accumulate due to a decrease of PSG, then leak into the blood producing complexed PSA to some extent in the cytoplasm. One factor analysis of variance (anova) on the correlation of tumor differentiation or Gleason score with serum values of total PSA, free PSA and a free/total PSA ratio demonstrated no significant links. Elucidation of secretory mechanisms should provide better comprehension of various PSA indices for prostate cancer screening.

[1]  J. McNeal,et al.  Prostate secretory granules in normal and neoplastic prostate glands: a diagnostic aid to needle biopsy. , 2000, Human pathology.

[2]  N. Konishi,et al.  ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen-assay-specific for complexed prostate-specific antigen. , 2000, Journal of immunological methods.

[3]  C. Paweletz,et al.  Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  J. Shimazaki,et al.  Immunohistochemical finding of α‐1‐antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer , 1999, International journal of urology : official journal of the Japanese Urological Association.

[5]  N. Konishi,et al.  A highly sensitive enzyme-linked immunoassay for serum free prostate specific antigen (f-PSA). , 1999, Clinica chimica acta; international journal of clinical chemistry.

[6]  J. McNeal,et al.  Characterization of cytoplasmic secretory granules (PSG), in prostatic epithelium and their transformation-induced loss in dysplasia and adenocarcinoma. , 1998, Human pathology.

[7]  T. Stamey,et al.  Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin. , 1998, The Journal of urology.

[8]  H. Lilja,et al.  Cloning and characterization of the α1‐antichymotrypsin produced by human prostate tissue , 1998 .

[9]  H. Schmid,et al.  In vivo and in vitro complex formation of prostate specific antigen with αi‐anti‐chymotrypsin , 1995 .

[10]  M. Brawer,et al.  Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. , 1995, Urology.

[11]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[12]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[13]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[14]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[15]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[16]  H. Lilja,et al.  Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. , 1987, The Journal of clinical investigation.

[17]  K. Watt,et al.  Human prostate-specific antigen: structural and functional similarity with serine proteases. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Lilja A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[19]  J. McNeal,et al.  Luminal contents of benign and malignant prostatic glands: correspondence to altered secretory mechanisms. , 2000, Human pathology.

[20]  H. Lilja,et al.  Cloning and characterization of the alpha 1-antichymotrypsin produced by human prostate tissue. , 1998, The Prostate.

[21]  T. Uchida,et al.  The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in japan , 1997, Cancer.

[22]  H. Schmid,et al.  In vivo and in vitro complex formation of prostate specific antigen with alpha 1-anti-chymotrypsin. , 1995, The Prostate.

[23]  W. Catalona,et al.  Comparison of different serum prostate specific antigen measures for early prostate cancer detection. , 1994, Cancer.

[24]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[25]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.

[26]  G. Murphy,et al.  Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.